Skip to content

Network pharmacology and molecular docking-based investigation of flavonoids against diabetes-associated inflammation: Mechanistic insights into a multi-target therapeutic approach.

Oct 2026 · Computational biology and chemistry · Vol 126 Pt 2, pp. 109454 · 0 citations · 46 references
Medicine

TL;DR

This study provides a comprehensive, multi-tiered mechanistic characterization of ten flavonoids against diabetes-associated inflammation through an integrated pipeline combining network pharmacology, protein-protein interaction (PPI) network analysis, and molecular docking.

Abstract

Background

Diabetes mellitus is a chronic metabolic disorder accompanied by persistent low-grade inflammation that drives the progression of debilitating diabetic complications. Flavonoids, a structurally diverse class of naturally occurring polyphenolic compounds, have demonstrated broad pharmacological activities encompassing anti-diabetic, anti-inflammatory, and antioxidant effects. Nevertheless, the multi-target molecular mechanisms underlying their therapeutic actions remain incompletely characterized, and the dynamic stability of their interactions with disease-relevant proteins has not been systematically evaluated.

Objective

This study aimed to systematically investigate the molecular mechanisms of ten flavonoids, including Isorhamnetin, Fisetin, Diosmetin, Baicalein, Rutin, Luteolin, Apigenin, Taxifolin, Hesperetin, and Baicalin, against diabetes-associated inflammation through an integrated pipeline combining network pharmacology, protein-protein interaction (PPI) network analysis, and molecular docking.

Methods

Diabetes- and inflammation-related target genes were retrieved from the GeneCards database using relevance score thresholds, and common targets shared among disease signatures and flavonoid compound targets were identified. A PPI network was constructed using the STRING database and subjected to topological analysis in Cytoscape to isolate core targets. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. Molecular docking was conducted using AutoDock Vina.

Results

A total of 111 co-targets were identified from diabetes-related genes (n = 1039), inflammation-related genes (n = 1044), and flavonoid drug targets (n = 193). PPI network analysis revealed 111 nodes and 1261 edges, with an average node degree of 22.7 and a highly significant PPI enrichment p-value < 1.0 × 10⁻¹ ⁶. Topological analysis identified ten core targets: AKT1, TNF, SRC, EGFR, BCL2, ESR1, HIF1-ALPHA, PTGS2 (COX-2), MMP9, and MAPK3. GO enrichment analysis indicated involvement in positive regulation of cell migration, response to oxidative stress, and negative regulation of signal transduction. KEGG analysis revealed enrichment in the HIF-1 and TNF signaling pathways, lipid metabolism and atherosclerosis, and endocrine resistance. The flavonoids exhibited favorable predicted binding affinities across the core targets, with docking scores ranging from -6.30 to -10.80 kcal/mol. Baicalin demonstrated the highest overall affinity, most notably with AKT1 (-10.80 kcal/mol), MAPK3 (-9.50 kcal/mol), and HIF1-ALPHA (-9.30 kcal/mol), while Luteolin showed superior binding to MMP9 (-10.10 kcal/mol).

Conclusion

This study provides a comprehensive, multi-tiered mechanistic characterization of ten flavonoids against diabetes-associated inflammation. Baicalin showed the most favorable predicted docking score among the evaluated flavonoid-target pairs, particularly against AKT1. These findings offer a rigorous scientific basis for the rational development of flavonoid-based therapeutic strategies for diabetic complications and establish a reproducible computational framework for prioritizing natural product leads in drug discovery.

View source

Similar papers

Network Pharmacology and Molecular Docking Approach to Identify and Investigate the Mechanisms of Active Components of Areca Catechu in Relation to Gut Disorders

It is found that catechin from Areca catechu holds significant potential as a therapeutic agent for gastrointestinal disorders, acting through the modulation of critical metabolic and inflammatory pathways.

Dina Aprillia Ariestine, D. Sari, Lambok Siahaan et al. · 0 citations
Open access Sep 2026

Elucidating the multitarget therapeutic potential of Camellia sinensis (Tea) phytochemicals using network pharmacology, functional annotation, and molecular docking

Findings provide mechanistic insights into the multi-target pharmacological potential of C. sinensis phytochemicals and highlight their prospective therapeutic relevance against cancer, metabolic, inflammatory, and neurodegenerative disorders.

Md. Mainuddin Hossain · 0 citations
Review Open access Sep 2026

Molecular mechanisms of herbal medicines and bioactive compounds in rheumatoid arthritis: a comprehensive network pharmacology perspective

Network pharmacology provides a robust framework for the mechanistic interpretation of herbal medicines and offers a promising opportunity to accelerate the discovery and clinical translation of safer, more effective therapies for RA.

T. Jasna, K. Sandra, Megh Pravin Vithalkar et al. · 0 citations
Open access Sep 2026

Multi-target computational pharmacology and molecular docking study of chromone-based flavonoids from Phyllanthus genus

Natural products continue to serve as a prolific source of bioactive scaffolds for drug discovery, particularly in the context of multifactorial diseases such as cancer and chronic inflammation. Chromone-based flavonoids derived from the Phyllanthus genus have attracted considerable attention due to their diverse pharm...

Mitali Bodhankar, Snehal J. Shrivastav, Shubham S. Gupta et al. · 0 citations
Open access Oct 2026

Deciphering the Multi-Target Mechanisms of Imeglimin in Type 2 Diabetes Mellitus Through Integrated Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

Findings provide a systems-level basis for further experimental validation of imeglimin mechanisms in T2DM and support stable interactions with SLC6A3, HTR2C, and GSK3B.

S. Krishnamoorthy, S. Sundararajan · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.